Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410976 · ClinicalTrials.gov registry record
Prospective Clinical Assessment Study in Children With Hypochondroplasia
A clinical trial of Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
- Recruiting
- Registry status
- 150
- Enrollment target
- 20
- Study locations
NCT06410976: Recruiting study of Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
NCT06410976 is a study of Hypochondroplasia that is actively recruiting participants, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 150 participants, roughly in line with the 158-participant average among 4 other Hypochondroplasia trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06410976, a study of Hypochondroplasia, is actively recruiting participants, sponsored by QED Therapeutics, a BridgeBio company.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Conditions Studied
Study Locations (20)
Other
- Hôpital Femme Mère Enfant HCL - Bron
- Hôpital Necker-Enfants Malades - Paris
- Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants - Toulouse
- Haukeland University Hospital - Bergen
- Paediatric Clinical Research Unit at Oslo University Hospital - Oslo
- Hospital Pediátrico de Coimbra - Coimbra
- KK Women's and Children's Hospital - Singapore
- Hospital Vithas San Jose - Vitoria-Gasteiz
Ontario
- London Health Sciences Centre - Children's Hospital of Western Ontario - London
- Children's Hospital of Eastern Ontario Research Institute - Ottawa
California
- UCSF Benioff Children's Hospital - Oakland
Colorado
- Childrens Hospital Colorado - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Maryland
- Johns Hopkins School of Medicine - Baltimore
Missouri
- University of Missouri - Columbia
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2026-10 |
What NCT06410976 shows while recruiting
NCT06410976 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 158-participant average among 4 other Hypochondroplasia trials with a reported enrollment target.
The record links to 1 condition, with Hypochondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06410976 names 20 study sites across 12 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT06410976 about?
NCT06410976 is a clinical study titled "Prospective Clinical Assessment Study in Children With Hypochondroplasia". This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
What is the current status of trial NCT06410976?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2026-10.
What conditions does trial NCT06410976 study?
This clinical trial studies the following conditions: Hypochondroplasia.
Who is sponsoring clinical trial NCT06410976?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410976 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypochondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
RECRUITING · Phase 2
-
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
RECRUITING
-
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
ACTIVE NOT RECRUITING · Phase 3
-
C-Type Natriuretic Peptide and Achondroplasia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI